



1/5/1

DIALOG(R) File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

008497090

WPI Acc No: 1991-001174/ 199101

XRAM Acc No: C91-000480

Bispecific and oligospecific mono- and oligo-valent receptors - used in therapy and diagnosis of malignant tumours

Patent Assignee: BEHRINGWERKE AG (BEHW); BEHRINGWERKE AG (BERI-N)

Inventor: BOSSLET K; HERMENTIN P; KUHLMANN L; SEEMANN G; STEINSTRASSER A;
STEINSTRASSER A; STEINSTRAS A

Number of Countries: 022 Number of Patents: 016

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 404097	A	19901227	EP 90111640	A	19900620	199101 B
DE 3920358	A	19910117	DE 3920358	A	19890622	199104
AU 9057621	A	19910103				199108
PT 94443	A	19910208				199109
CA 2019559	A	19901222				199111
JP 3048699	A	19910301	JP 90165485	A	19900622	199115
AU 639241	B	19930722	AU 9057621	A	19900621	199336
EP 404097	B1	19960904	EP 90111640	A	19900620	199640
DE 59010480	G	19961010	DE 510480	A	19900620	199646
			EP 90111640	A	19900620	
ES 2093623	T3	19970101	EP 90111640	A	19900620	199708
US 5591828	A	19970107	US 90541020	A	19900620	199708
			US 9317439	A	19930212	
			US 93147428	A	19931105	
			US 94317612	A	19940929	
IE 76715	B	19971022	IE 902254	A	19900621	199750
RU 2096459	C1	19971120	SU 4831122	A	19900621	199828
JP 2978210	B2	19991115	JP 90165485	A	19900622	199954
KR 183980	B1	19990401	KR 909252	A	19900622	200113
CA 2019559	C	20020108	CA 2019559	A	19900621	200206

Priority Applications (No Type Date): DE 3920358 A 19890622

Cited Patents: 3.Jnl.Ref; A3...9143; EP 141079; EP 369566; NoSR.Pub; US
4652440; WO 8601407

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
EP 404097	A				
					Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE
AU 639241	B			C12N-015/13	Previous Publ. patent AU 9057621
EP 404097	B1	G	39	C07K-016/18	
					Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LI LU NL SE
DE 59010480	G			C07K-016/18	Based on patent EP 404097
ES 2093623	T3			C07K-016/18	Based on patent EP 404097
US 5591828	A		29	C07K-016/46	Cont of application US 90541020
					Cont of application US 9317439
					Cont of application US 93147428
IE 76715	B			C12N-005/08	
RU 2096459	C1		29	C12N-015/13	
JP 2978210	B2		34	C07K-016/46	Previous Publ. patent JP 3048699
KR 183980	B1			C12N-015/13	
CA 2019559	C	E		C12N-015/62	

Abstract (Basic): EP 404097 A

The receptors (R) are obtained by fusion of DNA encoding VH and CH1 regions of antibodies of two or more specificity, with a suitable linker, and the expression of the above together with light chain gene

fragments, in an expression system. One R is directed towards an animal or human tumour associated antigen (TAA), and another has catalytic or enzymatic activity, e.g., R may have 3 TAA binding sites and one DTPA or EDTA binding site.

USE/ADVANTAGE - R is used in a pharmaceutical product for the treatment and diagnosis of malignant tumours. (38pp Dwg.No.0/21)

Title Terms: BI; SPECIFIC; OLIGO; SPECIFIC; MONO; OLIGO; VALENCE; RECEPTOR; THERAPEUTIC; DIAGNOSE; MALIGNANT; TUMOUR

Derwent Class: B04; C03; D16

International Patent Class (Main): C07K-016/18; C07K-016/46; C12N-005/08; C12N-015/13; C12N-015/62

International Patent Class (Additional): A61K-031/00; A61K-037/00; A61K-039/39; A61K-039/395; C07K-015/28; C07K-016/28; C12N-005/10; C12N-015/09; C12N-015/87; C12P-019/34; C12P-021/00; C12P-021/02; C12P-021/08; C12R-001-91

File Segment: CPI